Loading publications…
The last 5 uploaded publications
Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Rahul Aggarwal, Sylvie Rottey, Alice Bernard‐Tessier, Begoña Mellado, Takeo Kosaka, Walter M. Stadler, Lisa G. Horvath, Richard Greil, Bert H. O’Neil, Bilal A. Siddiqui, Thomas Bauernhofer, Mehmet Asım Bilen, Ferry A.L.M. Eskens, Shahneen Sandhu, Crystal Shaw, Changqing Ju, Benjamin E. Decato, Brian Yu, Ana M. Aparicio (2025). Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. , DOI: https://doi.org/10.1158/1078-0432.ccr-25-1211.
Article62 days agoSafety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Rahul Aggarwal, Sylvie Rottey, Alice Bernard‐Tessier, Begoña Mellado, Takeo Kosaka, Walter M. Stadler, Lisa G. Horvath, Richard Greil, Bert H. O’Neil, Bilal A. Siddiqui, Thomas Bauernhofer, Mehmet Asım Bilen, Ferry A.L.M. Eskens, Shahneen Sandhu, Crystal Shaw, Changqing Ju, Benjamin E. Decato, Brian Yu, Ana M. Aparicio (2025). Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. , DOI: https://doi.org/10.1158/1078-0432.ccr-25-1211.
Article62 days agoPhase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).
Rahul Aggarwal, Sylvie Rottey, Alice Bernard‐Tessier, Begoña Mellado-González, Takeo Kosaka, Walter M. Stadler, Shahneen Sandhu, Brian Yu, Crystal Shaw, Chia‐Hsin Ju, Corbin G. Thompson, Ana M. Aparicio (2024). Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).. , 42(16_suppl), DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.5012.
Article62 days agoManagement of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Ana M. Aparicio, Andrew J. Armstrong, Diogo Assed Bastos, Gerhardt Attard, Karol Axcrona, Mouna Ayadi, Himisha Beltran, Anders Bjartell, Pierre Blanchard, María T. Bourlon, Alberto Briganti, Muhammad Bulbul, Consuelo Buttigliero, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N., Caroline S. Clarke, Noel W. Clarke, Johann S. de Bono, Maria De Santis, Ignacio Durán, Eleni Efstathiou, Onyeanunam Ngozi Ekeke, Tamer I H El Nahas, Louise Emmett, Stefano Fanti, Omolara Fatiregun, Felix Y. Feng, Peter C.C. Fong, Valérie Fonteyne, Nicola Fossati, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Michael S. Hofman, Thomas A. Hope, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Anthony M. Joshua, R. Kanesvaran, Daniel Keizman, Raja B. Khauli, Gero Kramer, Stacy Loeb, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Mika Matikainen, Ray McDermott, Rana R. McKay, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Silke Gillessen, Fabio Turco, Ian D. Davis, Jason A. Efstathiou, Karim Fizazi, Nicholas D. James, Neal D. Shore, Eric J. Small, Matthew R. Smith, Christopher J. Sweeney, Bertrand Tombal, Thomas Zilli, Neeraj Agarwal, Emmanuel S. Antonarakis, Declan G. Murphy, Vedang Murthy, Shingai B.A. Mutambirwa, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Raphaële Renard‐Penna, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Shahneen Sandhu, Oliver A. Sartor, Edward M. Schaeffer, Howard I. Scher (2024). Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). , DOI: https://doi.org/10.1016/j.eururo.2024.09.017.
Article62 days agoPhase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTEimmune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
Rahul Aggarwal, Sylvie Rottey, Ana M. Aparicio, Richard Greil, Melissa A. Reimers, Shahneen Sandhu, Yiran Zhang, Mark Salvati, Nooshin Hashemi Sadraei (2022). Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTEimmune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).. , 40(6_suppl), DOI: https://doi.org/10.1200/jco.2022.40.6_suppl.tps197.
Article62 days ago